Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
114 hedge funds and large institutions have $1.11B invested in Y-mAbs Therapeutics in 2020 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 34 reducing their positions, and 7 closing their positions.
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
38% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 34
36% more capital invested
Capital invested by funds: $819M → $1.11B (+$292M)
8% more funds holding
Funds holding: 106 → 114 (+8)
1.9% more ownership
Funds ownership: 53.57% → 55.47% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$14.9M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$12.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11M |
| 4 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$10.1M |
| 5 |
Goldman Sachs
New York
|
+$6.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$12.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.96M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.97M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.95M |
| 5 |
Axa
Paris,
France
|
-$4.38M |
YMAB Hedge Fund Activity: Q4 2020 in Review
114 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2020, worth a combined $1.11B — up 36% from $819M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new YMAB positions and 7 closed out — a net gain of 9 holders — while 47 added to existing stakes and 34 trimmed.
The largest buyer was Artisan Partners, adding an estimated $14.9M. The largest seller was Sphera Funds Management, cutting an estimated $12.3M.
- 114 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2020, up from 106 in Q3 2020.
- Funds reported $1.11B of Y-mAbs Therapeutics stock for Q4 2020, up 36% quarter-over-quarter.
- 16 funds opened new Y-mAbs Therapeutics positions in Q4 2020 and 7 closed out, a net change of +9 holders.
- The largest Y-mAbs Therapeutics buyer in Q4 2020 was Artisan Partners, an estimated $14.9M added.
- The largest Y-mAbs Therapeutics seller in Q4 2020 was Sphera Funds Management, an estimated $12.3M sold.
Based on aggregated 13F filings for Q4 2020.